Dr. Uday Kundap
Clinical Trials Coordinator
Dr. Uday Kundap is a pharmacy graduate with a Ph.D. degree qualified in the field of Pharmacology and toxicology from Monash University, Malaysia and has a post-doctoral fellowship from the University of Montreal, Canada. He is interested in drug discoveries, clinical research, clinical trial monitoring and has 2 years of experience in projects related to clinical trials and BA-BE studies for investigational drugs, protocol writing, scientific publications, and international presentation. Before joining his PhD, he was working as a Project-coordinator and a Pharmacist at Lambda Therapeutics and Research in Mumbai, India. He completed his PhD from Monash University Malaysia in the field of neuropharmacology for projects related to cognitive dysfunction in epilepsy, reverse pharmacology for drug discoveries, and development of animal models for epilepsy in zebrafish. Dr Kundap was working as a Sr. Post-doctoral scientist at Pierre Drapeau-Eric Samarut’s research lab in the University of Montreal Hospital Centre (CRCHUM), Montreal, Canada for projects related to precision medicine for epilepsy, drug discoveries, pre-clinical model development, qPCR, Cre-LoxP technology for gene modification, Confocal-imaging, Loss of function - gene mutation in zebrafish animals and product development. Dr. Kundap has 17 scientific research publications with total citations of 273 with i10 index of 8 with 8506 publication downloads (Frontiers Loop) since 2017. He received a number of research and travel grants during his PhD and Postdoctoral studies. During his PhD from 2015 – 2019 he received US 10,000$ for travel related to research presentations in the field of epilepsy and neuroscience. He was also awarded a Monash University Graduate scholarship of RM 95,000 (Malaysian Ringgit) during his PhD. While pursuing his post-doctoral studies, he managed to receive a prestigious FRQS (Fonds de Recherche du Québec – Société) grant funding of CAD 135,000$ from the government of Quebec, Canada for 2019-2022.